These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6646986)

  • 1. The bioavailability of two new preparations of spironolactone tablets.
    Nijkerk AJ; Vermeer JM; Imanse M; De Vos D
    Pharm Weekbl Sci; 1983 Oct; 5(5):210-2. PubMed ID: 6646986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
    McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
    J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo availability of spironolactone from oral dosage forms.
    Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
    J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
    Lucchelli PD; Monarca A; Del Mastro S; Sega R
    Boll Chim Farm; 1978 Aug; 117(8):487-95. PubMed ID: 743391
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved bioavailability from a spironolactone beta-cyclodextrin complex.
    Yusuff NT; York P; Chrystyn H; Bramley PN; Swallow RD; Tuladhar BR; Losowsky MS
    Eur J Clin Pharmacol; 1991; 40(5):507-11. PubMed ID: 1884726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
    Rosenthal J; Jaeger H; Specker M
    Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
    Rameis H; Hitzenberger G; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of food on bioavailability of nalidixic acid from uncoated tablets having different dissolution rates.
    Ogata H; Aoyagi N; Kaniwa N; Ejima A
    J Pharmacobiodyn; 1984 Oct; 7(10):760-7. PubMed ID: 6520698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relative bioavailability of a new spironolactone preparation (author's transl)].
    Erking W; Lücker PW; Stöcker KP; Wetzelsberger K
    Arzneimittelforschung; 1979; 29(8):1184-9. PubMed ID: 583021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between the disintegration time and the bioavailability of vitamin C tablets.
    Bhagavan HN; Wolkoff BI
    Pharm Res; 1993 Feb; 10(2):239-42. PubMed ID: 8456071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
    Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
    Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of two tablet preparations of carbimazole in man.
    Shenfield GM; Ilett KF; Tjokrosetio R; Tearne P
    Clin Exp Pharmacol Physiol; 1979; 6(5):479-85. PubMed ID: 583031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.